KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Treasury Shares (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Treasury Shares for 16 consecutive years, with $4.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $4.1 billion, compared with a TTM value of $4.1 billion through Dec 2025, changed 0.0%, and an annual FY2025 reading of $4.1 billion, changed 0.0% over the prior year.
  • Treasury Shares was $107.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $106.0 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $107.0 million in Q4 2024 and bottomed at $24.4 million in Q4 2021.
  • Average Treasury Shares over 5 years is $94.8 million, with a median of $106.0 million recorded in 2021.
  • Peak annual rise in Treasury Shares hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Treasury Shares stood at $4.1 billion in 2021, then changed by 0.0% to $4.1 billion in 2022, then changed by 0.0% to $4.1 billion in 2023, then changed by 0.0% to $4.1 billion in 2024, then changed by 0.0% to $4.1 billion in 2025.
  • Business Quant data shows Treasury Shares for TEVA at $4.1 billion in Q4 2025, $4.1 billion in Q3 2025, and $4.1 billion in Q2 2025.